Fortitude Family Office’s Abeona Therapeutics ABEO Stock Holding History

Fortitude Family Office’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$297	Buy	+48	New	+$264	﹤0.01%	2056

Other funds holding ABEO

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Allied Private Wealth Boca Raton, Florida $156M AUM

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Darwin Wealth Management Tampa, Florida $365M AUM 22.69% 1-Year Est. Return

Fortitude Family Office's ABEO Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Abeona Therapeutics (ABEO) in Q2 2026: 48 shares worth $297. The stake represents ﹤0.01% of the portfolio and ranks #2056 among its holdings.

13 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

Fortitude Family Office held 48 shares of Abeona Therapeutics worth $297 as of Q2 2026.
Abeona Therapeutics was a new Fortitude Family Office position in Q2 2026.
Abeona Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #2056 holding.
13 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.